Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Smith & Nephew To Form US-based Biologics JV With Essex Woodlands - Update

RELATED NEWS
Trade SNN now with 

British medical technology firm Smith & Nephew Plc (SNN: Quote, SN.L) announced Wednesday that it has agreed to form a joint venture to further develop its Biologics and Clinical Therapies division with specialist healthcare growth equity and venture capital firm Essex Woodlands. The company expects the transaction to complete in the next few months and to be modestly earnings dilutive.

The new entity would be called Bioventus LLC, and will be 51 percent owned by Essex Woodlands and 49 percent by Smith & Nephew. In addition, Smith & Nephew will receive approximately $98 million cash, which will be used to pay down debt, and a $160 million 5-year note from Bioventus.

The transaction is subject to obtaining required regulatory approvals and satisfaction of other customary conditions.

Smith & Nephew will transfer the vast majority of its US Biologics team and Clinical Therapies business to the new entity. For the time being, the company will also continue to distribute Clinical Therapies products outside of the US. In 2010, Smith & Nephew's Biologics and Clinical Therapies business generated a trading profit of $44 million on revenues of $223 million.

The business will continue to be headquartered in Durham, North Carolina and the existing management team, led by its current President, Mark Augusti, will transfer to Bioventus. Smith & Nephew will retain its research facility at York, UK.

The company added that the new JV will continue to market its current portfolio of products, including the EXOGEN Ultrasound Bone Healing System and joint fluid therapy, and will seek to add further offerings.

Both Smith & Nephew and Essex Woodlands are committed to investing a significant proportion of Bioventus' cash flow into R&D over the next five years, the company said.

Smith & Nephew Chief Executive Officer Olivier Bohuon said, "In a single act we have given our existing Biologics business the resources to address longer-term development projects, retained access to the exciting area of orthobiologics, realised value for reinvestment in nearer-term opportunities, and freed up management resource to focus on driving efficiencies in established markets."

Essex Woodlands Founding Partner and Managing Director Marty Sutter stated that the company sees tremendous growth potential with this new venture as more patients discover how active products can help heal and treat joint and bone ailments without invasive surgery.

For the deal, Ondra Partners is serving as financial advisor, and Davis Polk & Wardwell LLP is serving as legal advisor, to Smith & Nephew.

Smith & Nephew shares closed Tuesday's trading at 623.25 pence, down 2.75 pence or 0.44 percent in London.

In the U.S., Smith & Nephew shares settled on Tuesday at $48.89, up $0.74 or 1.54 percent.

Register
To receive FREE breaking news email alerts for Smith & Nephew PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A ban on athletes using stamina-boosting gases - xenon and argon - came into effect on Monday. The World Anti-Doping Agency (WADA) said Hypoxia-Inducible Factor (HIF) activators Xenon and Argon have been added to the 2014 List of Prohibited Substances and Methods List following the required three-month notice period and UNESCO's communication to all States Parties. A recommendation to revise the British manufacturing growth eased further in August to its lowest level in 14 months as output and demand increased at slower rates, survey results from Markit Economics showed Monday. The Markit/CIPS Purchasing Managers' Index dropped to 52.5 from a revised 54.8 in July. Economists had expected the score to fall to 55.1 from July's original figure of 55.4. Consumers spent less in July than in the previous month, a surprise retreat that complicates the prevailing belief that the U.S. economic situation is improving. Along with the unexpected drop in spending, government figures released on Friday showed that incomes rose at a slower pace in July than in the previous month. Meanwhile, data on prices indicated that inflation pressures remain tame.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.